When treated with Gemcitabine (GEM), a Rad-51 inhibitor, there are better outcomes because of the presence of higher levels of chemotherapy at tumor sites, thereby reducing gastrointestinal side effects [9]. This evidence concerns the gene RAD51 and neoplasm.